Clinical Trial

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard "3+7" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2027-12-30 -> 2027-09-30 2026-06-16
Trial Details
NCT Number NCT07514936
Lead Sponsor Chinese PLA General Hospital
Collaborators: 940 Hospital of the People's Liberation Army Joint Logistic Support Force, The General Hospital of Western Theater Command, First Affiliated Hospital of Harbin Medical University, 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Conditions Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
Enrollment 120 participants
Start Date 2024-11-18
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-15